Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05571579
Recruiting Observational

Biological Collection of Brain Tumors

NCT05571579 · tracked via the Priya Life Science France tracker
Sponsor
Hospices Civils de Lyon
Phase
Observational
Started
2023-11-22
Last updated
2026-01-20

Condition(s) studied

Brain Tumor

Investigational drug(s) / intervention(s)

blood and/or csf collection →

blood and/or csf collection: blood and/or collection Only once : * 1 tube of blood of 4 mL on dry tube with or without gel, * 2 tubes of blood of 4 mL on EDTA tube, If CSF collected for diagnosis is available, it can be sent for storage in the collection.

Study summary

The objective of this study is to build a collection of biological samples from patients with brain tumors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient whose diagnosis of brain tumor has been confirmed. * Adult patients, from 18 years old and without upper age limit * Patient affiliated to a social security scheme or equivalent. * Patient able to consent, having dated and signed an informed consent Exclusion Criteria: * Pregnant or breastfeeding women * Patient under guardianship or curators. * Persons deprived of their liberty by a judicial or administrative decision

Primary outcome measure(s)

  • number of biological samples — 10 years
    number of biological samples

Trial sites (1)

FacilityCityRegionStatus
Hospices Civils de Lyon Bron Rhône Recruiting

More Hospices Civils de Lyon trials in France

Non-invasive Personalized Transcranial Cortical Neurostimulation for Pain Relief Recruiting
Validation of the French Version of the New Mobility Score (NMS) Recruiting
Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts Recruiting
Impact of Mental Health First Aid-trained Peers on the Mental Well-being of First-year Medical Residents. Active, not recruiting
Psychological Support Interventions for Women With Endometriosis (ENDOPSY) Starting soon

Other trials for the same condition

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma Active, not recruiting
Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features. Recruiting
Engineering Immune Organoids to Study Pediatric Cancer Recruiting
Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy Active, not recruiting
Genetic and Molecular Characterization of Nervous System Lesions Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05571579 on ClinicalTrials.gov ↗ ← All trials in France